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Abstract: The motor symptoms of Parkinson’s disease (PD), bradykinesia, muscular rigidity, 
and tremor depend upon degeneration of the dopaminergic neurons in the substantia nigra pars 
compacta. Recent neuropathological studies show that the Lewy bodies, the intraneuronal 
landmark of PD, accumulate in several neuronal cell types in the brain. An ascending gradient 
of pathological involvement, from the medulla oblongata to neocortical areas has been reported. 
Thus the original view of PD as a disease characterized by selective damage of the dopaminergic 
neurons in the mesencephalon should be updated into the concept of a severe multisystemic 
neurodegenerative disorder. Additionally, the neuropathological alterations outside the substantia 
nigra are soundly correlated with the non-motor symptoms of PD. As a result of these ﬁ  ndings, 
interest is growing in the identiﬁ  cation of prodromal non-motor symptoms of PD. Indeed, data 
from the literature suggest that autonomic disturbances, olfactory dysfunctions, depression 
and sleep disorders (in particular REM-sleep behavior disorder) may represent prodromal 
non-motor symptoms of PD. Several tests are available to detect most of these symptoms. Thus, 
the identiﬁ  cation of prodromal non-motor symptoms may contribute to the precocious diagnosis 
of PD, and might be useful in the future to test the efﬁ  cacy of neuroprotective agents.
Keywords: Parkinson’s disease, non-motor symptoms, autonomic dysfunction, olfactory 
dysfunction, depression, RBD
Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by 
bradykinesia, muscular rigidity, and tremor (Klockgether 2004). Among the three 
cardinal symptoms, bradykinesia is the most important and mainly contributes to the 
disability associated with PD progression. The term bradykinesia refers to the slowness 
and poverty of voluntary and involuntary movements characteristic of parkinsonism. 
Muscular rigidity, deﬁ  ned as the increased resistance of a joint to passive movements, 
only minimally contributes to the impairment experienced by parkinsonian patients. 
The subjective correlate of rigidity is a feeling of stiffness and reduced ability to relax 
limb and trunk muscles. Tremor is the most conspicuous of the cardinal symptoms of 
PD, and gave rise to the initial name of the disease, shaking palsy, by James Parkin-
son in 1817. Parkinsonian tremor usually occurs during rest, and typically affects the 
upper limbs, but may also occur in the legs and less frequently in the head. Although 
resting tremor is not necessarily disabling, many patients suffer considerably from it, 
not least because tremor stigmatizes them as parkinsonian subjects.
The cardinal motor symptoms of PD depend upon progressive degeneration of the 
dopamine-containing neurons in the substantia nigra pars compacta (Hughes et al 1992). 
The nigrostriatal dopaminergic damage can be monitored by functional neuroimaging 
techniques, such as positron emission tomography (PET) or single photon emission to-
mography (SPECT) (Eckert and Eidelberg 2005). Such methods contributed to establish Neuropsychiatric Disease and Treatment 2007:3(1) 146
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that approximately 50% reduction in dopaminergic nigrostriatal 
cells is required before clinical expression of the motor symptoms 
(Schwarz et al 2000; Marek et al 2001).
Therapy of PD is, at present, symptomatic, aimed at 
ameliorating clinical symptoms (Rascol et al 2002). Avail-
able drugs include levodopa, dopamine receptor agonists, 
anticholinergics, and antiglutamatergics. A more complete 
therapeutic approach to PD, however, should also be aimed 
at neuroprotection (slowing the progression of neuronal 
degeneration), neurorescue (normalizing injured neurons that 
are not yet dead), and neurorestoration (increasing the num-
ber of neurons by directly implanting new ones or causing 
existing cells to divide). Although functional neuroimaging 
data support the potential neuroprotective effect of some 
dopamine receptor agonists in PD (Parkinson Study Group 
2000; Whone et al 2003), the development of effective neu-
roprotective strategies is still limited by difﬁ  culties in making 
the correct diagnosis early during the course of illness.
Recent neuropathological data indicate that the pathologi-
cal landmark of PD, the Lewy bodies, can be identiﬁ  ed in 
several neuronal populations other than the dopaminergic 
mesencephalic ones (Braak et al 2003). Following the as-
cending gradient of neuronal involvement throughout disease 
progression, 6 neuropathological stages of PD have been 
identiﬁ  ed (Braak et al 2004): in stages 1 and 2, deﬁ  ned as 
“presymptomatic stages”, the Lewy bodies are conﬁ  ned to 
the anterior olfactory nucleus, olfactory bulb, dorsal motor 
nucleus of the glossopharyngeal and vagal nerves, locus coe-
ruleus, and reticular formation. In stages 3 and 4 (“interme-
diate stages”), the neuropathological damage extends to the 
substantia nigra pars compacta, other mesencephalic nuclei, 
the prosencephalon and meso-allocortical regions; during 
these stages, the motor symptoms develop and progressively 
worsen. Eventually, in stages 5 and 6 (“advanced stage” of 
PD), neocortical, prefrontal, and associative cortices are 
pathologically involved; in these latter stages, severe motor 
disturbances are accompanied by cognitive and behavioral 
symptoms. As a result of these neuropathological ﬁ  ndings, 
the original description of PD as due to the selective damage 
of dopaminergic neurons in the mesencephalon should be 
updated into the concept of a severe multisystemic neuro-
degenerative disorder, whose clinical symptoms reﬂ  ect the 
progression of the pathological involvement from the medulla 
oblongata to neocortical areas.
One of the most intriguing aspects of the studies by Braak 
et al (2003, 2004) is that the neuropathological alterations 
outside the substantia nigra are soundly correlated with 
some non-motor symptoms of PD. Thus, the identiﬁ  cation 
of early non-motor symptoms of PD and the application of 
instrumental methodologies may contribute to making the 
correct diagnosis of PD during the pre-motor stages. To this 
end, the identiﬁ  cation of genetic mutations responsible for 
hereditary forms of PD (Bonifati et al 2004) plays a crucial 
role, as it allows study of mutation carriers before the onset 
of the motor symptoms.
Based on the localization of Lewy bodies during the pre-
symptomatic stages of PD, the following non-motor symp-
toms may play a role as prodromal markers of the disease:
• Autonomic  disturbances
• Olfactory  dysfunctions
• Psychiatric  symptoms
•  Sleep disorders, in particular REM sleep behavior disor-
der (RBD)
Prodromal non-motor symptoms 
of PD
Autonomic disturbances
Dysautonomia is a key characteristic of multiple system 
atrophy (MSA), but occurs with varying severity in PD 
(Chauduri 2001). The pathophysiology of dysautonomia in 
PD is complex and includes degeneration and dysfunction 
of autonomic nuclei such as the dorsal vagal nucleus, the 
nucleus ambiguus, and other medullary nuclei which exert 
differential control on the sympathetic preganglionic neurons 
via descending pathways (Benarroch 1999). Additionally, 
degeneration of cholinergic, monoaminergic and serotonergic 
nuclei may cause abnormalities of modulatory effects within 
the central autonomic network (Benarroch 1999).
Subtle autonomic disturbances that can at least partly be 
related to the degeneration of the vagal nerve are an early 
and frequent sign in PD (Micieli et al 2003). Almost all PD 
patients suffer from constipation (Magerkurth et al 2005). An 
epidemiological study of 6790 men followed prospectively in 
the Honolulu Heart Program showed that men with less than 
one bowel movement per day had a 4.5-fold excess risk of 
developing PD versus men with more than two bowel move-
ments per day (Abbott et al 2001). These observations are 
compatible with the view that constipation is part of an early 
PD process. Nevertheless, such gastrointestinal symptoms 
are poorly speciﬁ  c in nature, besides being often aggravated 
by drugs such as tricyclic antidepressants.
Although troublesome dysautonomia is only thought to 
complicate advanced disease, cardiac meta-iodobenzylguanidine 
(MIGB) imaging challenges this view by showing early 
cardiac sympathetic denervation in PD and not multiple Neuropsychiatric Disease and Treatment 2007:3(1) 147
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system atrophy (Goldstein et al 2000). Cardiac sympathetic 
denervation has also been linked to genetic forms of PD with 
alpha-synuclein mutations (Singleton et al 2004).
Autonomic function in PD can be objectively assessed by 
several validated methods, including quantitative sudomotor 
axon reﬂ  ex test, urodynamic studies, defecating proctogra-
phy, tilt test, sympathetic skin response, and pupil function 
test with pilocarpine or phenylepinephrine (Bannister and 
Mathias 1999). In cases where distinction from MSA is 
needed, tests such as urethral sphincter electromyography, 
plasma norepinephrine concentration in response to head-up 
tilting, and clonidine-induced growth hormone challenge test 
may be useful (Bannister and Mathias 1999).
Olfactory dysfunctions
Olfactory disorders occur frequently in PD. More than 50% 
of patients suffering PD experience anosmia, 35% of patients 
have severe hyposmia and 14% of patients moderate hypos-
mia (Hawkes et al 1997; Muller et al 2002). The olfactory 
deﬁ  cit in PD shows above all an increase of olfactory thresh-
old, and minor alterations of identiﬁ  cative and discriminative 
functions (Tissingh et al 2001). The olfactory dysfunctions 
in PD depend on damage of the dopaminergic neurons in 
the olfactory bulb and olfactory nuclei. However, olfactory 
deﬁ  cit is not responsive to antiparkinsonian drugs and is not 
related to the severity of motor symptoms (Doty et al 1988, 
1992; Tissingh et al 2001). Such apparent discrepancy may 
depend on the precocious damage of the olfactory system in 
PD, which makes olfactory dysfunction already advanced at 
the time of onset of motor symptoms, ie, when the clinical 
diagnosis of PD is made.
Several lines of evidence suggest that olfactory dysfunc-
tion is a potential pre-motor marker of PD. Ansari and John-
son (1975) ﬁ  rst suggested the association between olfactory 
dysfunction and the development of PD. Subsequently, Doty 
et al (1988, 1992), Muller et al (2002), and Ponsen et al (2004) 
indicated hyposmia as a prodromal marker of the disease. 
Studies on healthy ﬁ  rst degree relatives of parkinsonians in 
families with hereditary or sporadic PD conﬁ  rmed that olfac-
tory dysfunctions may be a pre-motor marker of the disease: 
indeed, olfactory dysfunctions have been identiﬁ  ed in 41% 
of healthy subjects in families with autosomal dominant PD 
(Markopoulou et al 1997), and other studies reported that 
olfactory dysfunction is associated with an increased risk of 
developing PD among ﬁ  rst degree relatives of sporadic PD 
patients (Wolters et al 2000; Ponsen et al 2004).
Further data suggest that olfactory function may be a 
potentially useful test also to distinguish PD from atypical 
parkinsonism. In a controlled but unblinded study using the 
University of Pennsylvania Smell Identiﬁ  cation Test (UP-
SIT), patients with progressive supranuclear palsy (PSP) 
had similar olfaction to normal controls, but differed from 
patients with PD (Doty et al 1993). Using the same method, 
Wenning et al (1995) reported normal olfactory scores in PSP 
and corticobasal ganglionic degeneration, and signiﬁ  cantly 
worse scores in PD patients. Interestingly, patients with MSA 
scored worse than control, but signiﬁ  cantly better than PD. 
Finally, in a prospective study using the “snifﬁ  ng sticks”, all 
PD patients had moderate to severe hyposmia or anosmia, 
while patients with other parkinsonisms or essential tremor 
(ET) had normal or only mild to moderate hyposmia (Muller 
et al 2002). 
Psychiatric symptoms
Depression is extremely frequent in PD, occurring in up to 
45% of cases (Burns 2002). Depression is not necessarily 
related to the severity of motor symptoms of PD, and is often 
misdiagnosed since hypomimia and reduction of voluntary 
movements are common to both PD and pure depression. 
Therefore, the identiﬁ  cation of depression in PD patients is 
essentially based upon subjective perception of depressive 
symptoms such as feeling of incapability, reduced reaction 
to emotional stimuli, and inability to experience pleasure 
from things and events (anhedonia).
The pathophysiology of depression in PD is rather com-
plex, being related to damage of the noradrenergic, seroto-
nergic and dopaminergic pathways in the brain (Doder et al 
2000; Remy et al 2005). Indeed, the pattern of depressive 
symptoms in PD appears different from that of pure depres-
sion. Typical signs of depression in PD are a raised degree of 
dysphoria and irritability, pessimism about future, with low 
levels of inadequacy and sense of guilt (Remy et al 2005).
Interest in depression in PD has increased recently not 
only for the need of pharmacological treatment, but also for 
its potential role as a pre-motor marker of the disease. In a 
case-control study, the occurrence of depression in the last 
5 years was signiﬁ  cantly linked to future development of 
motor symptoms of PD (Shiba et al 2000). Similar ﬁ  ndings 
were drawn from a cohort study (Nilsson et al 2001). A 
longitudinal study showed the increased risk of developing 
PD in depressed subjects as compared to not depressed ones 
(Schurmann et al 2002). Finally, Lauterbach et al (2004) 
reported that patients with PD more often had a primary 
(preceding the onset of PD) diagnosis of single phobia and 
a secondary atypical depression than did those with dys-
tonia. In conclusion, although the pathophysiological and Neuropsychiatric Disease and Treatment 2007:3(1) 148
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neurochemical features linking the two disorders are not 
completely known, the correlation between depression and 
PD is consolidated to such a point that depression can be 
considered a non-motor sign of PD, potentially useful in the 
pre-motor stages of the disease.
Anxiety is also common in PD, and may represent a pre-
motor risk factor (Shiba et al 2000; Weisskopf et al 2003). 
Anxiety can be present as panic attacks, phobias, or gener-
alized anxiety disorder, and can be related to drug-induced 
motor ﬂ  uctuations in PD.
Sleep disorders
Virtually all PD patients develop sleep disruption, and there 
is evidence that the process usually begins early in the course 
of the disease (Chaudhuri 2003). Sleep disturbance in PD 
has a multifactorial etiology, but pathological degeneration 
of central sleep regulation centers in the brainstem and 
thalamocortical pathways is probably important (Saper 
et al 2001).
RBD is a speciﬁ  c disorder during the REM phase of 
sleep (Gagnon et al 2002), characterized by sudden motor-
behavioral episodes of violent nature, associated with atti-
tudes of defense from a threat and vocalizations. The oneiric 
experience lived by the patient, which almost always has a 
threatening and unpleasant content, is closely reﬂ  ected in 
his movements. Sometimes, the motor features are directed 
towards others.
Sleep disorders, and RBD in particular, are often seen 
in synucleinopathies such as PD, MSA, and diffuse Lewy 
body dementia (Shenk et al 1996; Olson et al 2000). The 
prevalence of RBD in PD is estimated at between 15% and 
33%, increasing to 58% if one takes into account subclini-
cal RBD (Shenk et al 1996). Some reports show that RBD 
evolves together with the motor symptoms in PD, and also 
that RBD can precede the onset of motor symptoms. In this 
respect, two epidemiological studies proved that PD develops 
in 40%–50% of subjects suffering RBD (Schenk et al 1996; 
Olson et al 2000). Moreover, the evidence of dopaminer-
gic nigrostriatal damage in RBD, as measured by SPECT 
(Eisensehr et al 2000), suggests that RBD can represent an 
early symptom of PD, in particular when associated with 
olfactory dysfunction (Stiasny-Kolster et al 2005).
In addition to RBD, recent data suggest that excessive 
daytime sleepiness may also be a pre-motor marker of PD 
(Abbott et al 2005). It is important to recognize excessive 
daytime sleepiness, as it can substantially affect quality of 
life in PD. A combination of the disease process, the effect 
of nocturnal sleep deprivation, and antiparkinsonian drugs is 
probably causative and, in some patients, excessive daytime 
sleepiness has been linked to the development of sudden-
onset sleep (Tracik and Ebersbach 2001).
Biomarkers
Neuropathological and clinical ﬁ  ndings suggest, therefore, 
that PD is a multisystemic neurodegenerative disorder, and 
that not-motor symptoms may play a role not only in deter-
mining functional impairment, but also as early markers of 
the disease.
Although autonomic or olfactory dysfunctions, psychiat-
ric symptoms and sleep disorders may represent prodromal 
markers of PD, it should be pointed out that none of these 
symptoms is speciﬁ  c to PD, since they all may occur as idio-
pathic disorders or during the course of other neurodegenera-
tive diseases, such as Alzheimer’s dementia (Idiaquez et al 
2002; Hoyt 2005; Burgut et al 2006; Hawkes 2006). Thus, the 
identiﬁ  cation of pre-motor signs in subjects at risk to develop 
PD needs to be associated with instrumental evidence of the 
damage to dopamine nigrostriatal pathway in order to make 
a correct presymptomatic diagnosis of the disease. 
Functional neuroimaging
One of the goals of functional neuroimaging is the pres-
ymptomatic detection of patients, and there are now several 
publications to suggest this may be possible. For example, 
patients with hemi-Parkinson’s disease showed reduced 
uptake of the ipsilateral as well as the expected contralateral 
side (Schwarz et al 2000), twin studies have shown a dopa-
minergic deﬁ  cit in asymptomatic twins of patients with PD 
(Burns et al 1992; Holthoff et al 1994; Lahinen et al 2000), 
and dopaminergic dysfunction has been shown in people 
after taking 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
prior to the onset of motor symptoms (Calne et al 1985). 
However, one unresolved issue with these studies is whether 
subjects with preclinical imaging abnormalities actually go 
on to develop PD, although data from one of the twin studies 
suggest that at least some do (Piccini et al 1997). Moreover, 
the high cost of these methodologies prevents their applica-
tion to the screening on wide populations of at risk subjects. 
Thus, interest is growing in the characterization of other tools 
that can contribute to the early identiﬁ  cation of the damage 
of dopaminergic neurons in PD.
Transcranial sonography
In 1995, Becker et al reported a highly characteristic en-
largement of echogenic signal (hyperechogenicity) of the 
substantia nigra in idiopathic PD. Since then, a number of Neuropsychiatric Disease and Treatment 2007:3(1) 149
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studies has been performed indicating that this method is a 
valuable tool for the differential diagnosis of PD, which even 
allows the identiﬁ  cation of subjects at risk for nigrostriatal 
dysfunction. Evidence that this method is indeed valid comes 
from the following ﬁ  ndings: (i) several groups independently 
demonstrated that the hyperechogenicity of the substantia 
nigra is a characteristic ultrasound ﬁ  nding in more than 90% 
of PD patients (Berg et al 2001; Walter et al 2002; Zedde 
et al 2005); (ii) the reproducibility is high, with very low 
inter rater variation (Berg et al 1999; 2001); (iii) prospec-
tive studies with two independent sonographers/raters, of 
whom at least one was blinded to the clinical data of patients, 
indicate a high predictive value of an association between 
hyperechogenicity of the substantia nigra and nigrostriatal 
impairment (Berg et al 1999; Walter et al 2003); (iv) sub-
stantia nigra hyperechogenicity indeed reﬂ  ects an alteration 
linked to nigrostriatal impairment, since it is larger contralat-
eral to the clinically more affected side (Berg et al 2001), it 
is present in PD but not ET, and only very rarely in atypical 
parkinsonian syndromes, such as striatonigral degeneration 
and PSP (Walters et al 2003; Niehaus et al 2004; Behnke 
et al 2005), and can be visualized in healthy subjects show-
ing mild impairment of the nigrostriatal system (Berg et al 
1999); (v) lastly, substantia nigra hyperechogenicity appears 
associated with the reduction of striatal 18F-dopa uptake in 
healthy subjects (Berg et al 1999, 2002) as well as in asymp-
tomatic parkin mutation carriers (Walter et al 2004), and in 
subjects with olfactory dysfunction (Sommer et al 2004). 
Thus transcranial sonography is a potential diagnostic tool 
in PD. It is attractive because it is a non-invasive, low risk 
test. However, more research needs to be performed to better 
determine if it is useful in the setting of diagnostic ambiguity 
early in the course of parkinsonism. Similarly, it remains to 
be established how well transcranial sonography performs 
in distinguishing PD and atypical parkinsonian syndromes, 
MSA in particular, and if it can be reliably used by multiple 
raters throughout the movement disorders centers.
Blood tests
PD is thought to be due, at least in part, to oxidative stress 
(Jenner 2003), and considerable effort has been spent in the 
search of a marker of this process. For example, patients 
with PD show a selective reduction in mitochondrial com-
plex I in the substantia nigra (Shapira et al 1990), as well 
as in their platelets (Parker et al 1989). The concentrations 
of several other potential markers of oxidative stress have 
been measured in the blood, such as malondialdehyde, su-
peroxide radicals (Ilic et al 1999), the coenzyme Q10 redox 
ratio (Gotz et al 2000), 8-hydroxy-2’-deoxyguanosine from 
oxidized DNA, and 8-hydroxyguanosine from RNA oxida-
tion (Kikuchi et al 2002; Abe et al 2003). The levels tend to 
be abnormal in PD compared with control groups, providing 
valuable insight into the nature of oxidative stress, but none 
is sufﬁ  ciently robust to be useful as a diagnostic marker of 
the disease process in the clinical practice. A similar situation 
exists if instead the levels of protective enzymes systems are 
compared, such as glutathione reductase, or copper and zinc 
superoxide dismutase (Ilic et al 1999).
An alternative approach may arise from studies dealing 
with peripheral dopamine system in PD. Studies on periph-
eral blood mononuclear cells have shown the reduction of 
intracellular dopamine concentrations (Caronti et al 1999), 
and tyrosine hydroxylase and dopamine transporter immuno-
reactivities (Caronti et al 1999; 2001). There is also evidence 
on the modulation of the expression of dopamine receptor 
mRNAs in the same cells (Nagai et al 1996; Barbanti et al 
1999). Although these ﬁ  ndings are very promising, further 
studies are necessary before considering such methods use-
ful for the differential diagnosis of PD as well as for the 
identiﬁ  cation of at risk subjects.
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